Brief: Zydus Lifesciences Says FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By USFDA
BRIEF-Zydus Lifesciences Says FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By USFDA Oct 13 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
FYB206 BECOMES FIRST PUBLICLY ANNOUNCED KEYTRUDA BIOSIMILAR ACCEPTED FOR REVIEW BY USFDA
Further company coverage: ZYDU.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka